Topic: food motivation

Glucagon like peptide (GLP-1) receptor agonists (GLP-1 RAs), such as Semaglutide, suppress food intake and are FDA approved to treat obesity. The primary mechanism of GLP-1 RAs involves interactions with the central nervous system, where GLP1 RA act in the hypothalamus or brainstem to reduce food intake. GLP-1 action on midbrain dopamine neurons in the VTA may also reduce food motivation and reward to suppress appetite. In addition to GLP1 RAs, new compounds with dual GLP1R and glucose-dependent insulinotropic polypeptide (GIP) receptor co-agonism, such as tirzepatide, show greater weight loss